We are really pleased to welcome Jean Marc Egly from the IGBMC, on September 4th invited by Laurent SCHAEFFER.
He will give a seminar at 11am entitled: “ Gene Expression Regulation , Drugs, Cancer, Sars -Cov-2 and… ”

 📍The seminar will be in the Amphi 3 Bis, 3rd floor.

 

Professional experience:

 Research Director, DRE Emeritus, INSERM (U1258; Strasbourg)

Member of the Science Academy (2005)

Distinguished Yushan Chair Prof. at the National Taiwan University, College of Medicine (2019-2025)

Honorary Yonglin Chair Prof NTU, College of Medicine, (2025-2028)

EMBO Member (2002)

Prof. at the Ecole Supérieure de Biotechnologie de Strasbourg (1982-1993)

Expert in Molecular Biology, Protein Chemistry, Biotechnology; Design of 15 products for chromatography.

Author 285 publications: Cell, Mol. Cell., Nature, Nat. Gen., Nat. Neuro., Nat. SMB., Science, EMBO, JBC.

Invited speaker, Keynotes at J. Monod, UCLA, Gordon, FEBS, IUB, Cold Spring Harbor, EMBO Meetings.

 

Scientific Boards

 – Oklahoma Medical Research Foundation (USA; 1996-00); Nation Research Agency against Aids (Paris, 1997- 02); French Delegate Biology, Medicine and Health (E.E.C., Brussels 1997-01); National Sequencing Center GENOSCOPE (Evry, Fr.; President; 1997-01); NATO, Cooperative Life Science and Technology (Brussels, 1999-02); Fondation pour la Recherche Medicale (2000-03); Inst. Curie (Paris, 1998-03); EUROGENTEC (Belgium., 2000-10) ; Inst. Biol. Mol Cell., IBMC (Porto, Portugal).

– Scientific Advisor near the Life Science Dept. CEO of Commissariat at the Atomic Energy (2003-07).

– Editorial Board of EMBO, Protein Purification, Molecular Endocrinology, DNA repair, Transcription

– Member of EMBO (1997) and of the American Society for Bioch. and Mol. Biol. (ASBMB).

– Member of the Swiss National Foundation: Evaluation of all the 12 years grants from 2003 to 2014)

– Chairman of the Scientific Council of the Association de la Recherche contre le Cancer (2006-2012)

– President of Comité Atip/Avenir Inserm/CNRS for recruiting young investigators (2004-14)

– Chairman of Scientific Council of the Inst.de Rech. Cancer de l’Appareil Dig. (2004-14)

– Scientific Advisor near the Chairman of Inserm (2007-14)

– Chairman of Scientific Council of Albert-Bonniot (Grenoble) and of CNCT, Université de Toulouse

– Member of the Parliamentary Office for Strategic & Techn. Projects Evaluation (Paris, 1998- 2016)

– Member of the Conseil de Prospective of the de French National Research Agency (2008-2016)

– Scientific Advisory Boards at : Centre de Recherche sur le Cancer de Toulouse (CRCT) (2014-18);   Institut Gustave Roussy (IGR), Villejuif, Fr (2016-20).

– Chairman of SAB Institute for Research on Cancer and Ageing of Nice (IRCAN) (2010- …)

– Member of the Scientific Council of Institut de Recherche sur le Development (IRD) (2017-2021)

– Scientific Adviser of Ksilink, a company with expertise in personalized medicine and drugs evaluation.

– Grants with Korea NSF (2014-2021), Spain (Pharma-Mar 2022) and ARC (2016-2019).

 

At the Present

 – Yonglin Chair Professor from the Yonglin Cancer Foundation of the NTU (Jan 2020- Dec 2028)

– Chang Gung Memorial Hospital Research, Scientific Adviser (2022-2028).

– Distinguished Prof. Sun Yet Tsen University, Med. School, Kaoschung, Tw. (2025-2028).

– Scientific Adviser, Pharma Mar, Spain.

 

Awards

– Chevalier de l’Ordre National du Mérite (1996) ; Officier de la Légion d’Honneur (2014).

– Tartois Award, Fondation pour la Recherche Médicale (1996).

– European Award Jeanne Loubaresse-Institut Curie for Advances in Cancer Research (1997).

– Descartes Research Award from the European Union (2000).

– AGF/Athena Award from the French Science Academy (2002).

– Grand Prix Institut National de la Santé et de la Recherche Medicale (INSERM) (2004).

– Duquesne Award from the Ligue nationale contre le Cancer de la ville de Paris (2009)

– Mitjaville Award from the French Académie Nationale de Médecine (2009)

– Grand Prix de la Fondation pour la Recherche Medicale (2012).

– European Research Council Advanced Grant Award: Top 5% (2009-1013).

– Chercheur Top 1% according to the Web of Knowledge (H index 83), 20,000 citations

Google Scholar (indice h 100, 30080 citations).

– Several grants Phar Mar., Science-Tech Tw (2025-2030); MoE (2025-2028); Compact (2025-2028).

 

Selected publications between 1990 and 2025 (among 290)

 

1. TBP : Cavallini et al. , A yeast activity can substitute for the HeLa cell TATA box factor., Nature (1988) 334, 77-80.

Cavalini et al., Cloning of the gene encoding the yeast protein BTF1Y, which can substitute for the human TATA box-binding factor PNAS (1989) 86, 9803-7.; Davison BL, Formation of stable preinitiation complexes between eukaryotic class B transcription factors and promoter sequences Nature (1983) 301, 680-6.

TFIIH :

2. Gerard, M., Fischer, L., Moncollin, V., Chipoulet and Egly, J.M. Purification and interaction properties of the human RNA polymerase B general transcription factor BTF2 (TFIIH). J. Biol. Chem. (1991) 266, 20940-20945.
3. Fisher, L., Gerard, M., Chalut, C., Lutz, Y., Humbert, S., Kanno, M., Chambon, P., and Egly, J.M. Cloning of the 62kD component of the basic transcription factor BTF2. Science (1992), 257, 1392-1395.
4. Lu,H., Zawel,L., Fisher,L., Egly,J.M. and Reinberg D. Human general transcription factor TFIIH phosphorylates the CTD-tail of RNA Polymerase II. Nature (1992), 358,641-645.
5. Schaeffer L., Roy R., Humbert S., Moncollin V., Vermeulen W., Hoeijmakers J.H.J., Chambon P. and Egly J.M. The basic transcription factor BTF2/TFIIH contains a helicase involved in both transcription and DNA repair. Science (1993), 260, 58-63. (Science N&V : DNA repair : molecule of the year).
6. Humbert S., van Vuuren H., Lutz Y., Hoeijmakers J.H.J., Egly J.M., Moncollin V. Characterization of p44 and p34 subunits of the BTF2/TFIIH transcription repair factor. EMBO (1994), 13, 2393-2398.
7. Van Vuuren A.J., Vermeulen W., Ma L., Weeda G., Appeldorn E. Jaspers N.G.J. van der Eb A.J., Hoeijmakers J.H.J and Humbert S., Shaeffer L., Egly J.M. Correction of Xeroderma repair defect by basal transcription factor BTF2/TFIIH. EMBO (1994), 13, 1645-1653.
8. Schaeffer L., Moncollin V., Roy R., Staub A., Mezzina V., Sarazin A., Weeda G., Hoeijmakers J.H.J. and Egly J.M. The ERCC2/DNA repair protein is associated with the class II BTF2/TFIIH transcription factor. EMBO (1994), 13, 2388-2392.
9. Roy R., Adamczewski J.P., Seroz T., Vermeulen W., Tassan J.P. Schaeffer L., Nigg E.A., Hoeijmakers J.H.J. and Egly J.M. MO15 kinase involved in cell cycle regulation is part of TFIIH the transcription/DNA repair factor. Cell (1994), 79, 1-9.
10. Aboussekra A., Biggerstaff M., Shivji M., Vilpo J., Moncollin V., Podust V., Protic M., Hubsher U., Egly J.M and Wood R.D. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell (1995), 80, 859-868.
11. Adamczewski J.P., Rossignol M., Tassan J.P., Nigg E.A., Moncollin V. and Egly J.M. MAT1, cdk7 and cyclin H form a kinase complex which is UV light sensitive upon association with TFIIH. EMBO (1996), 15, 1877-1884.
12. Marinoni J.C., R. Roy, W. Vermeulen, P. Miniou , Y. Lutz, G. Weeda, T. Seroz, E. Viegas-Péquignot, J.H.J. Hoeijmakers and J.M. Egly Cloning and characterization of p52, the fifth subunit of the core of the transcription/DNA repair factor TFIIH. EMBO (1997), 16, 1093-1102.
13. Rossignol M., Kolb-Cheynel I. and Egly J.M. Substrate specificity of the cdk-activating kinase (CAK) is altered upon association with TFIIH. EMBO (1997), 16, 1628-1637.

14 Rochette-Egly C., Adam S., Rossignol M., Egly J.M. and Chambon P. Stimulation of the activation function of RAR a through binding to the general transcription factor TFIIH and phosphorylation of cdk7. Cell (1997), 90, 97-107.

15. Vichi P., Coin F., Vermeulen W., Renaud J-P., J.H.J. Hoeijmakers, Moras D., and Egly J.M. Cisplatin- and UV- damaged DNA lure the basal transcription factor TBP/TFIID. EMBO (1997) 16, 7444-7456.
16. Coin F., Marinoni J.C., Rodolfo C., Fribourg S., Pedrini M.A. and Egly J.M. Mutations in XPD helicase prevent its interaction and regulation by p44 another subunit of TFIIH, resulting in XP and TTD phenotypes. Nature gen. (1998) 20, 184-189. (N&V)
17. Tirode F., Busso F., Coin F. and Egly J.M. Reconstitution of the transcription factor TFIIH: Assignment of functions for the three enzymatic subunits XPB, XPD and cdk7. Molecular Cell (1999), 3, 1-9.
18. Coin F., Bergmann E., Tremaud-Bravard A. and Egly J.M. Mutations in XPB and XPD helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH in transcription. EMBO (1999), 18, 1357-1366.
19. Araujo S. J., Tirode F., Coin F., Syvaoja J., Pospeich H., Syvaoja J. E., Stucki M., Hubscher U., Egly J.M. Wood R.D. Nucleotide excision repair of DNA lesion with recombinant human protein. Definition of the minimal set of factors, active forms of TFIIH and modulation by CAK. Gen. and Dev. (2000), 14, 349-359.
20. Chen D., Riedl Th., Washbrook E., Pace P.E., Combes R. Ch., Egly J.M. and Ali S. Recruitment of the basal transcription factor TFIIH by oestrogen receptor a activation function AF-2 results in the phosphorylation of Serine 118 within activation Function AF-1 by cdk7. Molecular Cell (2000), 6, 127-137.
21. Schultz P., Fribourg S., Poterszmann, Mallouh V., Moras D. and Egly J.M. Molecular structure of Human TFIIH. Cell, (2000), 102, 599-607.
22. Vermeulen, W., Bergmann E., Auriol J., Rademakers S., Frit Ph., Appeldoorn E., Hoeijmakers J.H.J. and Egly J.M. Sublimiting concentration of TFIIH transcription/DNA repair factor causes the trichothiodystrophy TTD-A disorder. Nature gen. (2000), 26, 307-313. (N. & V. from J. Pettrini).
23. Egly J.M. TFIIH: from transcription to clinic. The 14^th Datta Lecture. FEBS Lett. (2001), 24884, 124-128.
24. Keriel A., Stary A., Sarasin A., Rochette-Egly C. and Egly J.M. XPD mutations prevent TFIIH dependent transactivation by nuclear receptor and phosphorylation of RAR. Cell (2002), 109,125-135.

Preview : Mol Cell, 2002, and SAGE KE April 10, 2002 by J. Davenport.

25. Iben S., Tschochner H., Hoogsstraten D., Hozak P., Egly J.M. and Grummt I. TFIIH plays a role in RNA polymerase I transcription. Cell (2002), 109, 297-306.
26. Bradsher J., Auriol J., Proietti de Santis L., Iben S., Vonesch J.L., Grummt I. and Egly J.M. CSB is a component of RNA pol I transcription. Molecular Cell (2002), 10, 819-829.
27. Frit Ph., Kwon K., Coin F., Auriol J., Dubaele S., Salles B. and Egly J.M..Transcriptional activators stimulate DNA repair. Molecular Cell (2002), 10, 1391-1401.
28. Dubaele S., Proietti De Santis L., R. J. Bienstock, Keriel A., Stefanini M ., B. Van Houten and J.M. Egly. Basal transcription defect discriminates between Xeroderma Pigmentosum and Trichothiodystrophy in XPD patients. Molecular Cell (2003), 11, 1635-1646.
29. Riedl Th., Hanaoka F. and Egly J.M. The comings and goings of nucleotide excision repair factors on damaged DNA, EMBO (2003), 22, 5293-5303.
30. Le May N., Dubaele S., Proietti de Santis L., Billecocq A., Bouloy M. and Egly J.M. TFIIH transcription factor, a target for the Rift Valley Hemorrhagic Fever Virus. Cell, (2004), 116, 541-550.

Preview : Mol Cell, 2004, A. Dasgupta.

31. Compe E, Drané P., Laurent C., Dietrich K., Braun C., Hoeijmakers J.H.J. and Egly J.M. Dysregulation of the Peroxisome Proliferator-Activated Receptors target genes by XPD mutations. Mol. Cell. Biol. (2005), 6065-6076
32. Drané P., Compe E., Catez Ph., Chymkowitch P. and Egly J.M. Selective regulation of vitamin D receptor-responsive genes by TFIIH. Molecular Cell (2004), 16, 187-197.
33. Coin F., Auriol J., Tapias A., Clivio P., Vermeulen W. and Egly J.M. Phosphorylation of XPB as a switch to regulate TFIIH dependent DNA repair but not transcription. EMBO (2004), 23, 4835-46.
34. Coin F., Proietti De Santis L., Nardo T., Zlobinskaya O., Stefanini M. and Egly J.M. Within TFIIH, p8/TTD-A directs repair whereas cdk-activating kinase/CAK directs transcription. Molecular Cell (2006), 21, 215-226.
35. Lainé J.Ph., Egly JM. Initiation of DNA repair mediated by a stalled RNA polymerase IIO. EMBO (2006), 25, 387-97.
36. Proietti-De-Santis L. Drané P. and Egly J. M. Cockayne syndrome B protein regulates the transcriptional program of a specific subset of genes. EMBO (2006), 25, 1915-1923.
37. Charlet-B. N., Feuerhahn S., Kong S. E., Ziserman H., Conaway J. W., Conaway R. and Egly J. M. RNA polymerase II bypass of oxidative DNA damage is regulated by transcription elongation factors. EMBO (2006), 25, 5481-91.
38. Ito S., Kuraoka I., Chymkowitch P., Compe E., Takedachi A., Ishigami C., Coin F., Egly J.M.* and Tanaka K. XPG is required for the integrity of TFIIH and transactivation besides nucleotide excision repair: Implications for Cockayne syndrome in XP-G/CS patients. Molecular Cell (2007), 26, 231-244. Co-corresponding authors
39. Coin F., Oksenych V. and Egly J.M. DNA repair defect in Xeroderma pigmentosum group B is generated by a deficient stimulation of XPB ATPase activity by the p52 subunit of TFIIH. Molecular Cell (2007), 26, 245-256.
40. Compe E., Malerba M., Soler L., Marescaux J., Borrelli E. and Egly J.M. Neurological defects in Trichothiodystrophy reveal a coactivator function of TFIIH. Nature Neuro (2007), 10, 1423-32.
41. Mocquet V., Kropachev K., Kolbanovskiy M ., Kolbanovskiy A., Tapias A., Cai Y., Broyde S., Geacintov N.E. and Egly J.M. The human DNA repair factor XPC distinguishes stereoisomeric benzo(a)pyrenyl-DNA lesions. EMBO (2007), 26, 2923-32
42. Mocquet V., Lainé J.Ph., Riedl T., Yajin Z., Lee M.Y., and Egly J.M. * A new role for XPG in initiating a replication like process during the NER. EMBO (2008), 27,155-67.
43. Coin F., Okshenych V., Mocquet V., Groh S., Blattner C., and Egly JM*. Nucleotide excision repair driven by the dissociation of CAK from TFIIH; Molecular Cell, (2008), 31, 9-20. Co-corresponding authors
44. Kainov D. E., Vitorino M., Cavarelli J., Poterszman A. and Egly J.M.*. Structural basis for group A Trichothiodystrophy. Nat. Struc. Mol. Biol. (2008), 15, 980-984.
45. Oksenych V., Bernardes de Jesus B, Zhovmer A., Egly J.M.* and Coin F. Molecular insights into the recruitment of TFIIH to sites of DNA damage. EMBO (2009), 28, 2971-80. Co corresponding authors
46. Ueda T., Compe E., Catez Ph., Kraemer K.H. and Egly JM.* Both XPD alleles contribute to the phenotype of compound heterozygote xeroderma pigmentosum patients. J. Exp. Med. (2009), 206, 3031-3046. (Preview: JEM)
47. Le May N., Mota-Fernandes D., Vélez-Cruz R., Iltis I., Biard D. and Egly J.M.* NER factors are recruited to the promoters of activated genes and help chromatin modifications for efficient transcription in the absence of genotoxic attack. Molecular Cell (2010), 38, 54-66. (Cover of the issue)
48. Chymkowitch P., Le May N., Charneau P., Compe E., and Egly J.M.* The Phosphorylation of the Androgen Receptor by TFIIH directs the ubiquitin/proteasome process. EMBO (2011), 30, 468-79.
49. Feuerhahn S., Giraudon C, Martínez-Díez M., Bueren-Calabuig J. A., Galmarini C. M., Gago F. and Egly J.M*. XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic tetrahydroisoquinoline alkaloids. Chemistry & Biology (2011), 18, 988- 99. (Cover of the issue)
50. Hashimoto S., Boissel S., Zarhate M., RIO M., Munnich A., Egly J.M*., Colleaux L. MED23 Mediator subunit mutation links intellectual disability to dysregulation of immediate early gene expression. Science (2011), 333, 1161-63. Co corresponding authors.
51. Compe E. and Egly J.M.* TFIIH When Transcription met DNA repair. Nat. Rev. Mol. Cell. Biol. (2012), 13 343-354.
52. Le May N., Fradin D., Iltis I., Bougnères P. and Egly J.M.* XPG and XPF endonucleases trigger chromatin looping and DNA demethylation for accurate expression of activated gene. Molecular Cell (2012), 47, 622-632. Research Highlights: Nat. Rev. Genetics (2012), 13, 519.
53. Le May N., Iltis I., Amé J.C., Zhovmer A., Biard D., Egly J.M., Schreiber V. and Coin F.: Poly (ADP-Ribose) glycohydrolase regulates RAR mediated gene expression. Molecular Cell (2012), 48, 785-798 (Cover of the issue).

54.Vélez-Cruz R., Zadorin A., Coin F. and Egly J.M.* Sirt1 regulates RNA synthesis after UV irradiation in TFIIH-mutated cells: new insight into the XP-D/CS cellular phenotype. PNAS (2013), 110, 814-815; E212-20.

55. Abdulrahman W., Iltis I., Radu L., Braun C., Maglott-Roth A., Giraudon Ch., Egly J.M.* and Poterszman A. The ARCH domain of XPD, an anchoring platform for CAK that conditions TFIIH DNA repair and Transcription Activities. PNAS. (2013), 110, E633-42 Co corresponding authors
56. Oksenych V, Zhovmer A, Ziani S, Mari PO, Eberova J, Nardo T, Stefanini M, Giglia-Mari G, Egly J.M., Coin F. Histone Methyltransferase DOT1L Drives Recovery of Gene Expression after a Genotoxic Attack. PLoS Genet (2013), 9, 7, e1003611.
57. Kristensen U., Epanchintsev A., Rauschendorf M.A., Laugel V., Stevnsner T., Bohr V.A., Coin F. and Egly J.M.* Regulatory interplay of Cockayne Syndrome B ATPase and stress-response gene ATF3 following genotoxic stress. PNAS (2013), 110, E2261-2270.

2014

Alekseev A., Ayadi M., Brino L., Egly J.M., Larsen A.K. and Coin F. Identification of Spironolactone as a DNA repair inhibitor inducing the degradation of TFIIH. Chemistry & Biology (2014), 21, 398-407.

Bour G., Martel F., Goffin F., Bayle B., Gangloff J., Aprahamian M., Marescaux J. and Egly J.M.* Design and Development of a robotized system coupled to μCT imaging for intratumoral drug evaluation in a HCC mouse model; Plos One (2014), 2014 Sep 9;9(9):e106675.

Ziani S, Nagy Z, Alekseev S, Soutoglou E, Egly J.M., Coin F. Sequential and ordered assembly of a large DNA repair complex on undamaged chromatin. J Cell Biol. (2014), 206, 589-98

Arseni D., Lanzafame M., Compe E., Fortugno P., Afonso-Barroso A., Peverali F.a. , Lehmann A.R. , Zambruno G., Egly J.M., Stefanini M., Orioli D. TFIIH-dependent MMP-1 overexpression in trichothiodystrophy leads to extracellular matrix alterations in patient skin. PNAS (2015), 112, 1499-504

Kim J., Lim H., Saint-André C., Kim J., Sung S., Hwang CS., Egly J.M.*, and Cho Y*. The crystal structure of the Rad3/XPD regulatory domain of Ssl1/p44: Insights into regulation of the helicase activity of the XPD subunit of TFIIH, J. Bio. Chem. (2015), 290(13):8321-30.

Coin F.*, Egly J.M.* Revisiting the Function of CDK7 in Transcription by Virtue of a Recently Described TFIIH Kinase Inhibitor. Mol Cell. (2015), 59(4):513-4.

2016

Compe E. and Egly J.M.* Nucleotide Excision Repair and Transcriptional Regulation: TFIIH and Beyond; Annual Review of Biochemistry (2016), 85, 265-90.

Anastasina M, Le May N, Bugai A, Fu Y, Söderholm S, Gaelings L, Ohman T, Tynell J, Kyttänen S, Barboric M, Nyman TA, Matikainen S, Julkunen I, Butcher SJ, Egly J.M.*, Kainov DE. Biochim Biophys Acta. (2016), 1859(11):1440-1448.

Santamaría Nuñez G., Genes Robles C.M., Giraudon, C., Martínez-Leal J.F., Compe E., Coin F., Pablo Aviles, Galmarini C. M. and Egly J.M.* Lurbinectedin specifically triggers the degradation of phosphorylated RNA Polymerase II and the formation of DNA breaks in cancer cells. Mol. Cancer Ther. (2016), 15(10):2399-2412.

2017

Alekseev S., Nagy Z. Sandoz J., Weiss A., Egly J.M., Le May N. and Coin F. Transcription without XPB establishes a unified helicase-independent mechanism of promoter opening in eukaryotic gene expression Molecular Cell (2017), 65, 504-514.

Donnio L-M., Bidon B., Haschimoto S., May M., Epantchintsev A., Ryan C., Allen W., Hackett A., Gecz J., Skinner C., Stevenson R. E., de Brouwer A. P.M., Coutton C., Francannet C Jouk. P-S, Schwartz C. E. and Egly J.M.* MED12-related XLID disorders 1 are dose-dependent of immediate early genes 2 (IEGs) expression; HMG (2017), 11, 2062-2075

Radu L., Schoenwetter E., Braun C., Marcoux J., Koelmel W., Schmitt D. R., Kuper J., Cianferani S., Egly J.M*, Poterszman A. and Kisker C. The intricate network between the p34 and p44 subunits is central to the activity of the transcription/DNA repair factor TFIIH: NAR. (2017), 45, 10872-10883.

Epanchintsev A., Costanzo F., Rauschendorf M-A., Caputo M., Ye T., Donnio L.M., Proietti-de-Santis L., Coin F., Laugel V. and Egly J.M.* Cockayne syndrome A and B proteins regulate the timing of transcription arrest upon genotoxic stress through a ubiquitin/proteasome degradation process. Molecular Cell (2017), 68, 1054-66.

Hofrichter M, Nimtz L, Tigges J, Kabiri Y, Schröter F, Royer-Pokora B, Hildebrandt B, Schmuck M, Epanchintsev A, Theiss S, Adjaye J, Egly JM, Krutmann J, Fritsche E. Comparative performance analysis of human iPSC-derived and primary neural progenitor cells (NPC) grown as neurospheres in vitro. Stem Cell Res. 2017 Dec; 25: 72-82.

2018

Bidon B, Iltis I, Semer M, Nagy Z, Larnicol A, Cribier A, Benkirane M, Coin F, Egly J.M., Le May N. XPC is an RNA polymerase II cofactor recruiting ATAC to promoters by interacting with E2F1. Nat Com. (2018); 9(1):2610.

Tomita T, Ieguchi K, Takita M, Tsukahara F, Yamada M, Egly J.M., Maru Y. C1D is not directly involved in the repair of UV-damaged DNA but protects cells from oxidative stress by regulating gene expression in human cells. J Biochem. 2018 Dec 1; 164(6):415-426.

2019

Compe E., Genes C.M., Braun C., Coin F. and Egly J.M. TFIIE orchestrates the recruitment of the TFIIH kinase module at promoter before their release during transcription. Nat Com. 2019 May 7; 10 (1):2084.

Sandoz J., Nagy Z., Catez Ph., Caliskan G., Gény S., Renaud JB, Concordet JP, Poterszman A., Tora L., Egly J.M., Le May N. and Coin F. Functional interplay between TFIIH and the histone acetyl transferase KAT2A regulates higher-order chromatin structure and class II gene expression. Nat Com. 2019 Mar 20;10(1):1288.

Nizon M., Laugel V., Flanigan K., ., Egly J-M. and Isidor B. Variants in MED12L, encoding a subunit of the Mediator kinase module, are responsible for intellectual disability associated with transcription defect. Gen. in Med., 2019, june . doi3.

Semer M., Bidon B., Larnicol A., Caliskan G., Egly J-M., F. Coin and Le May N.: A mammalian DNA repair complex licences acetylation of histone variant H2AZ1 by KAT2A at active promoters during transcription.  Nat. Chem. Biol. (2019), 15(10):992-1000. doi: 10.1038/s41589-019-0354-y.

Depuis 2020

Epantchisev A., Rauschendorf M-A, Costanzo F., Calmels, N., Obringer, C., Sarasin, A., Coin, F., Laugel, V.* and Egly J-M* Defective Transcription of ATF3 responsive genes, a marker for Cockayne Syndrome, Science Rep. 2020; 10: 1105.

Peissert S, Sauer F., Grabarczyk D.B., Braun, C., Sander G., Poterszman A., Egly J-M*, Kuper J. and Kisker C. The Arch domain of XPD: a Hub that is mechanistically essential for the XPD helicase. Nat. Com. 2020, 11:1667.

Hashimoto, S. Takanari H., Compe, E. and Egly J-M*. Dysregulation of LXR responsive genes contribute to ichthyosis in Trichothiodystrophy. J of Derm. Science, 2020, 97, 3, 201-207.

Paccosi E, Costanzo F, Costantino M, Balzerano A, Monteonofrio L, Soddu S, Prantera G, Brancorsini S, Egly JM* and Proietti De Santis L*. CSA and CSB known as DNA repair factors, as part of a Ubiquitin-Proteasome degradation complex regulate cell division. PNAS, 2020 Nov 16:202006543. doi: 10.1073/pnas.2006543117. (IF:11.2)

Compe E. and Egly JM: The long road to understand RNAPII transcription initiation and related syndromes Annual Review of Biochemistry (2021), 90, 193-219. (IF: 23,6).

Berico P., Max Cigrang, Guillaume Davidson, Cathy Braun, Jeremy Sandoz, Stephanie Legras, Bujamin Vokshi, Nevena Slovic, Francois Peyresaubes, Carlos Mario Gene Robles, Egly Jean Marc., Compe E., Davidson I, and Coin F.: CDK7 and MITF repress a transcription program involved in survival and drug tolerance in melanoma; EMBO Rep, (2021), Sep 6;22(9):e51683. doi: 10.15252/embr.202051683. (IF:8?8)

Costanzo Federico, Marta Martínez Diez, Gema Santamaría Núnez, Juan Ignacio Díaz-Hernandéz, Carlos Maria Genes, Emmanuel Compe, Romeo Ricci, Tsai-Kun Li, Frederic Coin, Juan Fernando Martínez Leal, Eva Maria Garrido-Martin, and Jean Marc Egly. Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells EMBO Mol. Med. (2022 Mar 9): e14841. doi: 10.15252/emmm.202114841. (IF: 12,1)

Compe* Emmanuel, Evanthia Pangou, Nicolas Le May, Cathy Braun, Frédéric Coin, Izabela Sumara, Kwang-Wook Choi, Jean-Marc Egly. A phosphorylation mechanism conditions the partnership of the transcription/DNA repair factor XPD with the motor kinesin Eg5 in mitosis. Science Adv, 2022, Aug 19;8(33): eabp9457. doi: 10.1126/sciadv. abp9457.  (IF: 14,1)

Guh Chia-Yu, Hong-Jhih Shen, Liv Wei Chien Chen, Pei-Chen Chiu, Chen-Chia Lo, Yu-Hung Hsieh, Yi-Yun Chen, Tom Wei-Wu Chen, Liuh-Yow Chen, Ching-Shyi Wu, Jean-Marc Egly and Hsueh-Ping Chu. XPF activates break-induced telomere synthesis. Nat. com. 2022, Oct 2;13(1):5781. doi: 10.1038/s41467-022-33428-0. (IF:17,7).

Jeremy Sandoz, Max Cigrand, … Jean Marc Egly … Frederic Coin: Active mRNA degradation by EXD2 nuclease elicits recovery of transcription after genotoxic stress. Nat. com. 2023 2023 Jan 20;14(1):341. doi: 10.1038

Costanzo Federico^, Elena Paccosi, Luca Proietti de Santis, Jean Marc Egly*^, CSA, CSB and Ubiquitination: Orchestrating DNA Repair, Transcription, and Cell Cycle. Trends in Cell Bio, 2024, Oct;34(10):882-895. doi: 10.1016

Calles Antonio, Calvo Emiliano, Gema Santamaría Nuñez, Federico Costanzo, Maria José Guillén Navarro, Marta Martinez Diez, Aparna Gupta, Carmen Cuevas, Jean Marc Egly* and Pablo Aviles. Unveiling the Mechanism of Lurbinectedin’s Action and Its Potential in Combination Therapies in Small Cell Lung. Molecular Cancer Therapeutics, 2025. Jun 4;24(6):828-839.

Cigrang Max, Obid Julian, Nogaret Maguelone, Catez Philippe, Seno Léane, Ye Tao, Davidson Guillaume, Berico Pietro, Capelli Clara, Marechal Clara, Li Tsai-Kun, Compe Emmanuel, Avilés Pablo, Davidson Irwin, Egly Jean-Marc, Cuevas Carmen and Coin Frédéric. Novel synthetic ecteinascidins exhibit potent anti-melanoma activity by suppressing super-enhancer-driven oncogenic transcription. Nat. Com., 2025, Jan 8;16(1):512. doi: 10.1038

Ting-Kang Chang, Shiu-Ling Li, Anne-Cécile Brunac, Jia-Jun Huang, Pierre Brousset, Jean-Marc Egly, Tsai-Kun Li. Nitric Oxide Species Induce Topoisomerase II-dependent DNA Damage Responses Contributing to Colitis-associated Cancer Development. Com.Biology, 2025, submitted.